LGALS3 and candidiasis: By applying cell-permeable gal3 inhibitor TD139 on human neutrophils or administering it to mice with systemic candidiasis, our work raises the possibility that blockade of gal3 in neutrophils may be a promising therapeutic strategy for systemic Candida infection.